Join us for a presentation by Luciane Cavalli, Ph.D., on her research into the epidemiology of pediatric central nervous system tumors in Brazil. Cavalli will be at Georgetown University as part of the Translational Research on Pediatric Cancers in Brazil research collaboration between Georgetown and Research Institute Pele Pequeno Principe. The purpose of this collaboration, conducted along with Georgetown University professors of oncology Nina Kadan-Lottick, M.D., MSPH, and Christopher Loffredo, Ph.D., is to bring together population health and basic/translational scientists who are interested in the global dimensions of childhood cancer research.
Following the presentation, attendees will have the opportunity to discuss new projects related to global health, childhood cancer research, cancer prevention and control, diagnosis, therapeutics, and survivorship care for adolescents and young adults.
The event is co-sponsored by the Global Health Institute, Georgetown Lombardi Survivorship Research Initiative, and the Lombardi Comprehensive Cancer Center.
Featured
Luciane Cavalli, Ph.D., is a professor at Research Institute Pele Pequeno Principe in Curitiba, Brazil, and an adjunct professor of oncology at Georgetown University. She has been involved in cancer research for the past 30 years, primarily the study of genomic instability, one of the key hallmarks of cancer. Her research focuses on the identification of somatic alterations at the genomic, transcriptomic, and epigenomic levels using state-of-art cytogenetic and molecular biology integrative approaches. Her group has identified molecular markers that can be directly translated into the reduction of breast cancer mortality through prevention and early diagnosis. More recently, Cavalli has expanded her research into pediatric tumors, with focus on neuroblastoma and central nervous system tumors. Current projects involve the use of multi-omics approaches to liquid biopsies for predicting and monitoring treatment response, as well as the development of patient-derived reprogrammed cell and tumor-derived pluripotent cells models to investigate tumor heterogeneity and resistance mechanisms, ultimately guiding translational applications in pediatric oncology.